Floatz logo

Revaree Plus

Hormone-receptor-positive Breast Cancer

Memorial Sloan Kettering Cancer CenterPhase 4 / ApprovedActive
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
89/ 100

Competitive context

116 Active assets in the Hormone-receptor-positive Breast Cancer cohort.

Asset / SponsorPhaseRating
EXEMESTANE
Fujian Cancer Hospital
Phase 4BBB
Everolimus
Ellipses Pharma
Phase 4BBB
Arimidex
University of Illinois at Chicago
Phase 4BBB
Palbociclib
BeOne Medicines
Phase 3BBB
Ribociclib
BeOne Medicines
Phase 4BBB

View all 50 →

Same molecule, other indications

Revaree Plus is also rated in:

breast carcinoma in situDormant
BB
Indicative ·
65 / 100
View asset →
breast cancerDormant
CCC
Indicative ·
54 / 100
View asset →
breast carcinomaDormant
NR
Indicative ·
/ 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →